ArticleDrug delivery and translational research2026
Preparation of cancer cell membrane-coated Gambogic acid-loaded pH-sensitive liposomes to enhance targeted anti-hepatocellular carcinoma effect.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Current Status and Emerging Trends in Global Research on Liposome Therapy for Hepatocellular Carcinoma: A Bibliometric Analysis.Journal of hepatocellular carcinoma · 2026Article
- Progress of siRNA Nanomedicines in Modulating the Microenvironment of Triple-Negative Breast Cancer.International journal of nanomedicine · 2026Review
- Dual-Targeting CSC Therapy: Acid-Responsive Cisplatin/CaCOPharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Hepatocellular carcinoma has an insidious onset, and therefore, most patients are already in the middle or advanced stage once diagnosed, which seriously affects the prognosis of the patients. For a long time, it has been difficult to achieve the expected effect of the treatment that can effectively deal with the middle-or-late -stage liver cancer. Gambogic acid (GA), a dry resin secreted by the Garcinia hanbaryi Hook.f., is a natural active ingredient with various biological activities, especially the strong anti-hepatocellular carcinoma activity. However, the drawbacks such as high toxicity to the liver and kidney and low solubility have greatly limited its application. Therefore, it is necessary to develop suitable Gambogic acid formulations to overcome these disadvantages. In this study, injectable HepG2 cell membrane-modified pH-responsive liposomes (PEOz/GA@HepG2m) were prepared for active targeted delivery of Gambogic acid for the treatment of hepatocellular carcinoma. The physicochemical properties of PEOz/GA@HepG2m were evaluated in terms of the drug loading efficiency, particle size, morphology and drug release. The inhibitory effect of PEOz/GA@HepG2m on the proliferation of hepatocellular carcinoma cells was assessed by CCK8 assay and calcein-AM/PI assay in vitro. The effect of unloaded liposome PEOz@HepG2m on cellular internalization was assessed in different cell lines and it's in vivo biodistribution was analyzed by near-infrared (NIR) fluorescence imaging. The antitumor effect of PEOz/GA@HepG2m in vivo was evaluated in HepG2 tumor-bearing nude mice. The PEOz@HepG2m liposomes exhibit excellent targeting ability toward HepG2 cells. PEOz/GA@HepG2m possesses high delivery efficiency and a remarkably therapeutic effect both in vitro and vivo. The coating HepG2 cell membrane could significantly enhance the tumor-targeting effect of the liposomes and improve the antitumor effect of the loaded drug GA in vivo, indicating that the active-targeting biomimetic liposome, PEOz/GA@HepG2m, is a promising nanoplatform for delivery of drugs to hepatocellular carcinoma.
Indexed as
Identifiers
40819158What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.